MedTrace Logo

A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer

NCT04514159 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2023-02-01

No results posted yet for this study

Summary

This is a Phase 1b, open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of ZN-c5 administered orally in combination with abemaciclib (VERZENIO®) in participants with advanced estrogen-receptor positive, human epidermal growth factor receptor-2 negative (ER+/HER2-) breast cancer.

Conditions

Interventions

DRUG

ZN-c5

ZN-c5 is the study drug.

DRUG

Abemaciclib

Abemaciclib (VERZENIO®) is an approved drug.

Sponsors & Collaborators

  • Zeno Alpha Inc.

    lead INDUSTRY

Principal Investigators

  • Carrie Brownstein, MD · Zeno Alpha Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-12
Primary Completion
2022-10-24
Completion
2022-10-24
FDA Drug
Yes

Countries

  • United States
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04514159 on ClinicalTrials.gov